Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Wagner, D; Karitnig, R; Wienerroither, V; Hau, HM; Lederer, A; Sucher, R; Kornprat, P.
Sarcopenic Obesity Promotes Recurrence in Patients Undergoing Resection for Colorectal Liver Metastases (CRLM).
Anticancer Res. 2024; 44(5): 2177-2183. Doi: 10.21873/anticanres.17024
Web of Science PubMed FullText FullText_MUG

Führende Autor*innen der Med Uni Graz: Wagner Doris
Co-Autor*innen der Med Uni Graz: Hau Hans-Michael; Karitnig Robert; Kornprat Peter; Sucher Robert; Wienerroither Valerie Fanny
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND/AIM: Sarcopenia, is predictive of a worse outcome after resection for colorectal liver metastases (CRLM). Obesity leads to a metabolic double burden if sarcopenia is as present, prompting malignancy progression, known as sarcopenic obesity (SO). This study aimed to compare sarcopenia and SO in patients undergoing CRLM resection, to prognostic parameters. PATIENTS AND METHODS: The skeletal muscle index (SMI) defined sarcopenia using sex specific cut off values (48.4 cm²/m² for females and 59.1 cm²/m² for males) by calculating the preoperative muscle mass at the vertebral height L3 using OSIRIX DICOM viewer. SO was determined as sarcopenia in patients showing obesity, as shown via fat percentage measurements on the preoperative CT scan. Established prognostic parameters (KRAS status, TNM classification, inflammatory response) were evaluated against SMI and SO to assess their predictability for postoperative outcomes. RESULTS: A total of 251 patients (62% female, median age 68 years) were included. Sarcopenic patients showed a threefold higher risk for postoperative death as compared to non-sarcopenic patients (p=0.04). Prevalent SO increased this risk to fivefold (p=0.01) compared to non-sarcopenic patients. COX regression analysis revealed SO and KRAS positivity as independent prognostic factors for disease-free survival (SO: p=0.038; KRAS: p=0.041; TNM, tumor size, Charlson Comorbidity Index, platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio all not significant). Patients risk of death in case of KRAS positivity and SO was seven times higher (p=0.03). CONCLUSION: There seems to be a benefit in merging data on mutational status and muscle wasting in patients with CRLM to facilitate an individual, patient-tailored approach.
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Sarcopenia - pathology, etiology; Female - administration & dosage; Male - administration & dosage; Colorectal Neoplasms - pathology, surgery; Liver Neoplasms - secondary, surgery; Obesity - complications; Aged - administration & dosage; Middle Aged - administration & dosage; Prognosis - administration & dosage; Neoplasm Recurrence, Local - pathology; Hepatectomy - adverse effects; Aged, 80 and over - administration & dosage; Disease-Free Survival - administration & dosage
Find related publications in this database (Keywords): Colorectal liver metastases; sarcopenia; sarcopenic obesity; recurrence-free survival; recurrence